- Home
- DAVEW vs BRTX Comparison
DAVEW vs BRTX Comparison
Compare DAVEW & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVEW
- BRTX
- Stock Information
- Founded
- DAVEW 2015
- BRTX 1997
- Country
- DAVEW United States
- BRTX United States
- Employees
- DAVEW 274
- BRTX N/A
- Industry
- DAVEW Retail: Computer Software & Peripheral Equipment
- BRTX Managed Health Care
- Sector
- DAVEW Technology
- BRTX Health Care
- Exchange
- DAVEW Nasdaq
- BRTX Nasdaq
- Market Cap
- DAVEW N/A
- BRTX 12.6M
- IPO Year
- DAVEW N/A
- BRTX N/A
- Fundamental
- Price
- DAVEW $1.43
- BRTX $1.60
- Analyst Decision
- DAVEW
- BRTX Strong Buy
- Analyst Count
- DAVEW 0
- BRTX 1
- Target Price
- DAVEW N/A
- BRTX $18.00
- AVG Volume (30 Days)
- DAVEW 46.1K
- BRTX 151.8K
- Earning Date
- DAVEW 03-06-2025
- BRTX 08-12-2025
- Dividend Yield
- DAVEW N/A
- BRTX N/A
- EPS Growth
- DAVEW N/A
- BRTX N/A
- EPS
- DAVEW 3.12
- BRTX N/A
- Revenue
- DAVEW $319,355,000.00
- BRTX $391,000.00
- Revenue This Year
- DAVEW N/A
- BRTX $391.52
- Revenue Next Year
- DAVEW N/A
- BRTX $3.50
- P/E Ratio
- DAVEW $34.00
- BRTX N/A
- Revenue Growth
- DAVEW 30.00
- BRTX 161.54
- 52 Week Low
- DAVEW $0.28
- BRTX $1.21
- 52 Week High
- DAVEW $0.32
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- DAVEW N/A
- BRTX 45.93
- Support Level
- DAVEW N/A
- BRTX $1.51
- Resistance Level
- DAVEW N/A
- BRTX $1.79
- Average True Range (ATR)
- DAVEW 0.00
- BRTX 0.10
- MACD
- DAVEW 0.00
- BRTX -0.00
- Stochastic Oscillator
- DAVEW 0.00
- BRTX 32.14
About DAVEW Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.